This study investigates rare oligometastatic cancers. The purpose is to explore the effects of adding stereotactic body radiotherapy (SBRT) to the standard treatment.
The study evaluates how the addition of SBRT impacts overall survival. It looks into the effectiveness of combining this radiotherapy with existing treatments.
- Who can participate: Adults aged 18 and older with rare oligometastatic cancers can join. Key factors include having 1-5 metastases and a life expectancy greater than 6 months.
- Study details: Participants will either receive standard treatment alone or with added stereotactic body radiotherapy.
How understandable was the trial content above?
Hard to understand
Easy to understand